Subcutaneous Bioavailability and Flip-Flop Kinetics

Why Route and Rate Both Matter

A subcutaneous dose can produce a different concentration-time profile from an intravenous dose for two distinct reasons. First, only a fraction of the administered dose may reach systemic circulation. Second, the drug may enter circulation gradually from the injection depot. These effects should not be conflated: incomplete systemic availability changes total exposure, while slower absorption can change the profile’s timing and shape even when total exposure is unchanged.

The earlier material on subcutaneous depot absorption and lag time introduced the depot input concept. Here the focus is how bioavailability and the absorption rate affect exposure and how slow absorption can make the observed terminal decline appear to reflect absorption rather than elimination.

Definition: Subcutaneous bioavailability, \(F\), is the fraction of an administered subcutaneous dose that reaches systemic circulation as unchanged drug. Under linear pharmacokinetics, \(0\leq F\leq1\). Flip-flop kinetics occur in a model with first-order absorption and elimination when absorption is slower than elimination, so the terminal concentration decline is governed by the absorption rate constant rather than the elimination rate constant.

Model and Concentration-Time Profile

Consider a single subcutaneous dose \(D\) at time zero. Assume a single, well-mixed systemic compartment with volume \(V\), linear elimination with clearance \(CL\), and first-order absorption from the depot with rate constant \(k_a\). Let a fraction \(F\) of the administered dose enter systemic circulation. The model treats the remaining fraction as unavailable to the systemic compartment; it does not specify the physical cause of that loss. Assume no additional input, dose-dependent kinetics, or distribution compartments, and initially assume no lag time.

The depot amount declines exponentially, and the systemic amount \(A(t)\) changes according to the difference between absorption input and elimination. The elimination rate constant is \(k_e=CL/V\). With \(A(0)=0\), the equations are:

A_{\text{depot}}(t)=D e^{-k_a t}, \qquad \frac{dA}{dt}=F k_a D e^{-k_a t}-k_e A, \qquad C(t)=\frac{A(t)}{V}.

For distinct rate constants, solving the amount equation gives the Bateman concentration profile:

C(t)=\frac{F D}{V}\frac{k_a}{k_a-k_e} \left(e^{-k_e t}-e^{-k_a t}\right), \qquad k_a\ne k_e.

Although the coefficient can be negative when \(k_a<k_e\), the concentration remains nonnegative: in that case \(e^{-k_e t}<e^{-k_a t}\), so both the coefficient and the parenthesized difference are negative. If \(k_a=k_e\), taking the limit gives \(C(t)=(FD/V)k_a t e^{-k_a t}\).

Worked Example: Deriving and Checking a Subcutaneous Profile

Suppose, hypothetically, that a \(100\) mg dose has \(F=0.80\), \(V=20\) L, \(k_a=0.12\) h\(^{-1}\), and \(k_e=0.30\) h\(^{-1}\). Calculate the profile at \(t=5.00\) h and determine its peak time.

Substitute the values into the model:

C(t)=\frac{(0.80)(100\ \mathrm{mg})}{20\ \mathrm{L}} \frac{0.12\ \mathrm{h}^{-1}}{0.12\ \mathrm{h}^{-1}-0.30\ \mathrm{h}^{-1}} \left(e^{-0.30t}-e^{-0.12t}\right).

The constant multiplier is \(4.00\times(-0.6667)=-2.667\) mg/L. At \(t=5.00\) h, \(e^{-1.50}=0.2231\) and \(e^{-0.600}=0.5488\), so:

C(5.00)=(-2.667)(0.2231-0.5488)=0.8685\ \mathrm{mg/L}.

Setting the derivative of the profile to zero yields \(t_{\max}=\ln(k_a/k_e)/(k_a-k_e)\). Thus \(t_{\max}=\ln(0.12/0.30)/(0.12-0.30)=5.091\) h. The concentration calculated at 5.00 h is therefore close to the peak, as expected. The negative multiplier does not imply a negative concentration; the exponential difference is also negative.

Exposure, Peak Timing, and Flip-Flop

Integrating the concentration profile from zero to infinity gives the area under the concentration-time curve, \(AUC\). For this model, the result depends on the systemically available dose and clearance, not on \(k_a\). This is a mass-balance result: if the same amount eventually enters the system and clearance is linear, changing the rate of entry redistributes concentration over time but does not change the total area.

AUC_{0-\infty}=\int_0^\infty C(t)\,dt =\frac{F D}{V}\frac{k_a}{k_a-k_e} \left(\frac{1}{k_e}-\frac{1}{k_a}\right) =\frac{F D}{V k_e} =\frac{F D}{CL}.

The time of the maximum concentration follows by differentiating \(C(t)\) and setting the derivative to zero. For \(k_a\ne k_e\), the resulting equality is \(k_e e^{-k_e t}=k_a e^{-k_a t}\), which gives:

t_{\max}=\frac{\ln(k_a/k_e)}{k_a-k_e}.

When the rates are equal, the limiting value is \(t_{\max}=1/k_e\). The expression gives a positive time for either ordering of the two rates. It also shows that a change in \(k_a\) can move the peak even if \(F\), dose, volume, and clearance remain fixed.

The terminal phase is determined by the slower exponential in the profile. If \(k_a>k_e\), the \(e^{-k_a t}\) term diminishes more quickly, leaving a terminal decline governed by \(k_e\). If \(k_a<k_e\), the \(e^{-k_e t}\) term diminishes more quickly, leaving a terminal decline governed by \(k_a\). The latter is flip-flop kinetics. The apparent terminal half-life calculated from the subcutaneous profile is then \(\ln(2)/k_a\), not the systemic elimination half-life \(\ln(2)/k_e\).

Worked Example: Identifying a Flip-Flop Terminal Phase

In the hypothetical profile above, \(k_a=0.12\) h\(^{-1}\) and \(k_e=0.30\) h\(^{-1}\). Since \(k_a<k_e\), absorption is slower than elimination. At sufficiently late times, the \(e^{-0.30t}\) contribution has become small relative to \(e^{-0.12t}\), and the concentration declines approximately in proportion to \(e^{-0.12t}\). Therefore, the terminal slope on a log-concentration plot is approximately \(-0.12\) h\(^{-1}\).

The apparent terminal half-life is \(\ln(2)/0.12=5.776\) h. In contrast, the elimination half-life implied by the independently specified \(k_e\) is \(\ln(2)/0.30=2.310\) h. A subcutaneous terminal slope alone would not justify reporting \(0.30\) h\(^{-1}\) as the elimination rate: in this example it reflects slow absorption. An intravenous profile under the same linear systemic disposition would help establish the elimination rate independently.

For these parameters, \(CL=k_eV=(0.30\ \mathrm{h}^{-1})(20\ \mathrm{L})=6.00\) L/h. The total exposure is \(AUC=(0.80)(100\ \mathrm{mg})/(6.00\ \mathrm{L/h})=13.33\) mg·h/L. The long apparent terminal half-life does not alter that model-based area; it reflects the slow delivery of the dose.

Bioavailability and Absorption-Rate Changes

Under the stated linear assumptions, incomplete bioavailability scales the whole profile by \(F\): reducing \(F\) reduces concentrations and \(AUC\) in the same proportion if all other parameters stay fixed. The dose-normalized subcutaneous AUC is \(AUC/D=F/CL\). It therefore identifies the ratio \(F/CL\), not \(F\) and \(CL\) separately. A reference estimate of systemic clearance, such as one obtained from an intravenous dose under comparable conditions, is needed to estimate \(F\) from exposure.

Worked Example: Estimating Incomplete Bioavailability From Exposure

Suppose a hypothetical drug has known linear systemic clearance of \(5.00\) L/h. A \(100\) mg subcutaneous dose with \(F=0.60\) has model-predicted exposure \(AUC=FD/CL\). Compare this with an intravenous \(100\) mg dose.

For the subcutaneous dose, \(AUC=(0.60)(100\ \mathrm{mg})/(5.00\ \mathrm{L/h})=12.0\) mg·h/L. For the intravenous dose, \(F=1\), so \(AUC=(100\ \mathrm{mg})/(5.00\ \mathrm{L/h})=20.0\) mg·h/L. The ratio of dose-normalized AUCs is \(12.0/20.0=0.600\), consistent with \(F=0.60\).

If clearance were not known independently, the subcutaneous exposure alone would imply \(CL/F=D/AUC=100/12.0=8.333\) L/h. That quantity is apparent clearance, not a separate estimate of \(CL\) or \(F\). Assigning both a clearance and a bioavailability from the same AUC without additional information would overstate what the observation identifies.

Changing \(k_a\) has a different signature from changing \(F\). When \(F\) and clearance are unchanged, the model predicts the same \(AUC\) but a changed peak time and peak concentration. A slower absorption rate typically delays and lowers the peak. If it becomes slower than \(k_e\), it also changes which rate controls the terminal slope.

Worked Example: Changing Absorption Rate Without Changing Exposure

Consider a hypothetical \(120\) mg subcutaneous dose with \(F=0.75\), \(V=30\) L, and \(k_e=0.20\) h\(^{-1}\). Compare \(k_a=0.80\) h\(^{-1}\) with \(k_a=0.10\) h\(^{-1}\). In both cases \(CL=k_eV=6.00\) L/h, so \(AUC=(0.75)(120\ \mathrm{mg})/(6.00\ \mathrm{L/h})=15.0\) mg·h/L.

For \(k_a=0.80\) h\(^{-1}\), the profile is \(C(t)=4.00(e^{-0.20t}-e^{-0.80t})\) mg/L. Its peak time is \(\ln(0.80/0.20)/(0.80-0.20)=2.310\) h. Substitution gives \(C_{\max}=4.00(e^{-0.4621}-e^{-1.848})=1.890\) mg/L. Since \(k_a>k_e\), the terminal slope reflects elimination.

For \(k_a=0.10\) h\(^{-1}\), the profile is \(C(t)=-3.00(e^{-0.20t}-e^{-0.10t})\) mg/L. The peak time is \(\ln(0.10/0.20)/(0.10-0.20)=6.931\) h, and \(C_{\max}=-3.00(e^{-1.386}-e^{-0.6931})=0.750\) mg/L. Now \(k_a<k_e\), so the terminal slope reflects absorption. The equal AUCs alongside different peaks and terminal slopes illustrate why exposure alone does not describe the full profile.

Diagnostics, Alternatives, and Limitations

A straight-looking terminal segment on a semilog concentration-time plot is not sufficient evidence that its slope equals systemic elimination. Sparse late sampling, concentrations near the assay’s quantification limit, or a sampling window that misses the transition between exponential components can make the slope uncertain. A useful interpretation asks which rate is independently supported and whether the data cover both the rising and declining phases. If the observed terminal half-life differs substantially between routes or formulations while systemic disposition is expected to be unchanged, absorption-limited decline is one possibility to investigate, not a conclusion from the profile alone.

The Bateman model is a deliberately compact alternative to richer descriptions. It is useful when the systemic disposition is adequately represented by one compartment and depot release is approximately first order. A measured intravenous profile can provide an independent systemic disposition comparison; dose-normalized AUC can assess relative exposure when the doses are in the linear range. By contrast, fitting a subcutaneous profile alone may leave \(k_a\), \(k_e\), and \(F/CL\) poorly distinguished, particularly with limited sampling. A lag time shifts the onset of the profile and the peak time but, in this ideal model with complete eventual release of the available fraction, does not change \(AUC\).

The model can mislead if elimination is nonlinear, systemic disposition is not one-compartment, absorption is not first-order, or the dose does not ultimately behave as the assumed available fraction. In those cases, a terminal phase may contain more than the two exponentials in the model, and estimates of \(F\), \(k_a\), or \(k_e\) can be biased. Diagnostics include checking whether the assumed profile systematically misses observed concentrations, whether parameter estimates change markedly with the sampling window, and whether independently measured disposition is compatible with the fitted values. A good numerical fit by itself does not establish that the fitted terminal rate is elimination.

Common pitfall: “The terminal slope after a subcutaneous dose is the elimination rate, so its half-life is the systemic elimination half-life.” This is only justified when absorption is faster than elimination and the model’s other assumptions hold. If \(k_a<k_e\), the terminal slope is \(-k_a\); an independent disposition reference or other identifying information is needed to separate absorption from elimination.

Check Your Understanding

Answer each question, then compare your reasoning with the solutions below.

A subcutaneous dose follows the model with \(k_a=0.08\) h\(^{-1}\) and \(k_e=0.25\) h\(^{-1}\). Which rate governs the terminal slope, and what is the apparent terminal half-life?
A linear drug has \(D=80\) mg, \(F=0.50\), and \(CL=4.00\) L/h. Calculate \(AUC_{0-\infty}\).
If \(F\), \(D\), and \(CL\) stay constant but \(k_a\) decreases, does the model predict a change in AUC? Name two profile features that can change.
Why can a subcutaneous AUC by itself fail to identify both \(F\) and \(CL\)?

Solutions. (1) Since \(k_a<k_e\), absorption governs the terminal slope, approximately \(-0.08\) h\(^{-1}\). The apparent terminal half-life is \(\ln(2)/0.08=8.664\) h. (2) \(AUC=FD/CL=(0.50)(80\ \mathrm{mg})/(4.00\ \mathrm{L/h})=10.0\) mg·h/L. (3) No. \(AUC=FD/CL\) remains fixed, while \(t_{\max}\), \(C_{\max}\), and possibly the terminal slope can change. (4) The subcutaneous AUC identifies \(F/CL\) through \(AUC/D=F/CL\); multiple \(F\) and \(CL\) pairs can have the same ratio, so an independent estimate or additional information is required.